RIVELA, PAOLO
 Distribuzione geografica
Continente #
EU - Europa 113
AS - Asia 24
NA - Nord America 21
Totale 158
Nazione #
IT - Italia 67
IE - Irlanda 19
US - Stati Uniti d'America 19
DE - Germania 11
HK - Hong Kong 10
SG - Singapore 10
FI - Finlandia 6
SE - Svezia 5
CZ - Repubblica Ceca 4
CA - Canada 2
CN - Cina 2
IN - India 2
RO - Romania 1
Totale 158
Città #
Dublin 19
Hong Kong 10
Milan 6
Singapore 5
Brno 4
Helsinki 4
Munich 4
Alba 3
Asti 3
Frankfurt am Main 3
Modena 3
Viareggio 3
Alessandria 2
Cadelbosco di Sopra 2
Campi Salentina 2
Carpi 2
Espoo 2
Florence 2
Genoa 2
Giussano 2
Montepaone Lido 2
Mumbai 2
Mülheim 2
Novara 2
Oderzo 2
Pinerolo 2
Rimini 2
Rome 2
Roosevelt 2
Taranto 2
Thorold 2
Venice 2
Arona 1
Ashburn 1
Boardman 1
Bremen 1
Chandler 1
Iasi 1
Lawrence 1
Naples 1
Padova 1
Princeton 1
Totale 117
Nome #
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 47
Comparative clinical value of pharmacologic therapies for B-cell chronic lymphocytic leukemia: an umbrella analysis 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 26
Adoptive immunotherapy by Donor Lymphocyte Infusion (DLI) after allogeneic Hematopoietic Stem Cell transplantation and chimerism monitoring 22
Monitoraggio del chimerismo prima e dopo infusione di linfociti (DLI) in trapianti allogenici di cellule staminali ematopoietiche (CSE). 21
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 12
The black swan: a case of central nervous system graft-versus-host disease 10
Totale 165
Categoria #
all - tutte 1.148
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.148


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223 0 0 0 0 0 0 0 0 0 0 1 2
2022/202344 1 1 2 0 1 1 0 7 16 1 12 2
2023/202460 2 3 3 3 6 1 16 0 3 4 6 13
2024/202558 20 1 18 14 5 0 0 0 0 0 0 0
Totale 165